Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SUTENT (SUNITINIB, SU11248) in Patients With Recurrent or Progressive Glioblastoma Multiforme An Academic Prospective Single-Arm Phase II Clinical Trial Including Translational Research Studies.

Next Previous
X
Search
Trial Profile

SUTENT (SUNITINIB, SU11248) in Patients With Recurrent or Progressive Glioblastoma Multiforme An Academic Prospective Single-Arm Phase II Clinical Trial Including Translational Research Studies.

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Jul 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sunitinib (Primary)
  • Indications Glioblastoma
  • Focus Therapeutic Use

    • Most Recent Events

    • 20 Jul 2022 This trial has been completed in Germany according to European Clinical Trials Database record.
    • 27 Aug 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 27 Aug 2010 Planned end date changed from 1 Jun 2010 to 1 Jan 2011 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top